BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to assess the effect of treatment with a monoclonal
antibody called atezolizumab in patients diagnosed with a type of lung cancer called
malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and
tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with
standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be
investigated.